4 ms·
Identification of Pre-Existing Immunity to Cas9 Proteins (CRISPR) in Humans
- capitaltryst 9y agoIANAS, but I do not believe that immunity will be a gating issue - pretty straightforward solutions on that front including 1) ex vivo treatment 2) tweaking Cas9 to make it undetectable by the immune response 3) varying the Cas9 variant 4) Cpf1 orthologs 5) nanoparticle delivery 6) intracellular expression may not be inhibited 7) suppress the immune response 8) treating organs that do not engender the immune trigger (e.g. eyes). Some of the brightest scientists of our time are advancing the science daily, I would not think they would be stymied by something so obviously foreseeable and circumventable. This is definitely something to be addressed, but the recent headline and twitter echo chamber was dramaticized to maximize in-feed virality. Immunity is a distant third in terms of hurdles and already has clearly identifiable workarounds - efficient somatic delivery and enhancing specificity w minimal off-target impact are of far greater priority. Just my $0.02.